Xencor | XNCR - Cost Of Sales


Xencor reported $61.66M in Cost of Sales for its fiscal quarter ending in June of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Cytokinetics USD 160K 104.24M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
J&J USD 8.07B 103M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Xencor USD 61.66M 50.95M Jun/2025